334 related articles for article (PubMed ID: 17003839)
21. Generation of a human induced pluripotent stem cell line (UEFi004-A) from a patient with progressive myoclonic epilepsy type 1 (EPM1).
Singh S; Plotnikova L; Karvonen K; Ryytty S; Hyppönen J; Kälviäinen R; Hämäläinen RH
Stem Cell Res; 2023 Dec; 73():103248. PubMed ID: 37951142
[TBL] [Abstract][Full Text] [Related]
22. Reduced cystatin B activity correlates with enhanced cathepsin activity in progressive myoclonus epilepsy.
Rinne R; Saukko P; Järvinen M; Lehesjoki AE
Ann Med; 2002; 34(5):380-5. PubMed ID: 12452481
[TBL] [Abstract][Full Text] [Related]
23. A pathogenetic hypothesis of Unverricht-Lundborg disease onset and progression.
Franceschetti S; Sancini G; Buzzi A; Zucchini S; Paradiso B; Magnaghi G; Frassoni C; Chikhladze M; Avanzini G; Simonato M
Neurobiol Dis; 2007 Mar; 25(3):675-85. PubMed ID: 17188503
[TBL] [Abstract][Full Text] [Related]
24. Molecular background of progressive myoclonus epilepsy.
Lehesjoki AE
EMBO J; 2003 Jul; 22(14):3473-8. PubMed ID: 12853462
[TBL] [Abstract][Full Text] [Related]
25. Refining the phenotype of Unverricht-Lundborg disease (EPM1): a population-wide Finnish study.
Hyppönen J; Äikiä M; Joensuu T; Julkunen P; Danner N; Koskenkorva P; Vanninen R; Lehesjoki AE; Mervaala E; Kälviäinen R
Neurology; 2015 Apr; 84(15):1529-36. PubMed ID: 25770194
[TBL] [Abstract][Full Text] [Related]
26. Insights into the Genetic Profile of Two Siblings Affected by Unverricht-Lundborg Disease Using Patient-Derived hiPSCs.
Lucchino V; Scaramuzzino L; Scalise S; Lo Conte M; Zannino C; Benedetto GL; Aguglia U; Ferlazzo E; Cuda G; Parrotta EI
Cells; 2022 Nov; 11(21):. PubMed ID: 36359887
[TBL] [Abstract][Full Text] [Related]
27. Progressive myoclonus epilepsy [EPM1] repeat d(CCCCGCCCCGCG)n forms folded hairpin structures at physiological pH.
Pataskar SS; Dash D; Brahmachari SK
J Biomol Struct Dyn; 2001 Oct; 19(2):293-305. PubMed ID: 11697734
[TBL] [Abstract][Full Text] [Related]
28. A novel c132-134del mutation in Unverricht-Lundborg disease and the review of literature of heterozygous compound patients.
Assenza G; Benvenga A; Gennaro E; Tombini M; Campana C; Assenza F; Di Pino G; Di Lazzaro V
Epilepsia; 2017 Feb; 58(2):e31-e35. PubMed ID: 27888502
[TBL] [Abstract][Full Text] [Related]
29. Advances in the genetics of progressive myoclonus epilepsy.
Delgado-Escueta AV; Ganesh S; Yamakawa K
Am J Med Genet; 2001; 106(2):129-38. PubMed ID: 11579433
[TBL] [Abstract][Full Text] [Related]
30. SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure.
Dibbens LM; Michelucci R; Gambardella A; Andermann F; Rubboli G; Bayly MA; Joensuu T; Vears DF; Franceschetti S; Canafoglia L; Wallace R; Bassuk AG; Power DA; Tassinari CA; Andermann E; Lehesjoki AE; Berkovic SF
Ann Neurol; 2009 Oct; 66(4):532-6. PubMed ID: 19847901
[TBL] [Abstract][Full Text] [Related]
31. Allelic heterogeneity of Mediterranean myoclonus and the cystatin B gene.
Labauge P; Ouazzani R; M'Rabet A; Grid D; Genton P; Dravet C; Chkili T; Beck C; Buresi C; Baldy-Moulinier M; Malafosse A
Ann Neurol; 1997 May; 41(5):686-9. PubMed ID: 9153533
[TBL] [Abstract][Full Text] [Related]
32. Identification of mutations in cystatin B, the gene responsible for the Unverricht-Lundborg type of progressive myoclonus epilepsy (EPM1).
Lalioti MD; Mirotsou M; Buresi C; Peitsch MC; Rossier C; Ouazzani R; Baldy-Moulinier M; Bottani A; Malafosse A; Antonarakis SE
Am J Hum Genet; 1997 Feb; 60(2):342-51. PubMed ID: 9012407
[TBL] [Abstract][Full Text] [Related]
33. Intramolecular i-motif structure at acidic pH for progressive myoclonus epilepsy (EPM1) repeat d(CCCCGCCCCGCG)n.
Pataskar SS; Dash D; Brahmachari SK
J Biomol Struct Dyn; 2001 Oct; 19(2):307-13. PubMed ID: 11697735
[TBL] [Abstract][Full Text] [Related]
34. Unverricht-Lundborg disease in a five-generation Arab family: instability of dodecamer repeats.
Mazarib A; Xiong L; Neufeld MY; Birnbaum M; Korczyn AD; Pandolfo M; Berkovic SF
Neurology; 2001 Sep; 57(6):1050-4. PubMed ID: 11571333
[TBL] [Abstract][Full Text] [Related]
35. Reduced serotonin and 3-hydroxyanthranilic acid levels in serum of cystatin B-deficient mice, a model system for progressive myoclonus epilepsy.
Arbatova J; D'Amato E; Vaarmann A; Zharkovsky A; Reeben M
Epilepsia; 2005; 46 Suppl 5():49-51. PubMed ID: 15987253
[TBL] [Abstract][Full Text] [Related]
36. The Roles of Cystatin B in the Brain and Pathophysiological Mechanisms of Progressive Myoclonic Epilepsy Type 1.
Singh S; Hämäläinen RH
Cells; 2024 Jan; 13(2):. PubMed ID: 38247861
[TBL] [Abstract][Full Text] [Related]
37. Thickened skull, scoliosis and other skeletal findings in Unverricht-Lundborg disease link cystatin B function to bone metabolism.
Suoranta S; Manninen H; Koskenkorva P; Könönen M; Laitinen R; Lehesjoki AE; Kälviäinen R; Vanninen R
Bone; 2012 Dec; 51(6):1016-24. PubMed ID: 23010349
[TBL] [Abstract][Full Text] [Related]
38. A PCR amplification method reveals instability of the dodecamer repeat in progressive myoclonus epilepsy (EPM1) and no correlation between the size of the repeat and age at onset.
Lalioti MD; Scott HS; Genton P; Grid D; Ouazzani R; M'Rabet A; Ibrahim S; Gouider R; Dravet C; Chkili T; Bottani A; Buresi C; Malafosse A; Antonarakis SE
Am J Hum Genet; 1998 Apr; 62(4):842-7. PubMed ID: 9529356
[TBL] [Abstract][Full Text] [Related]
39. Abnormal microglial activation in the Cstb(-/-) mouse, a model for progressive myoclonus epilepsy, EPM1.
Okuneva O; Körber I; Li Z; Tian L; Joensuu T; Kopra O; Lehesjoki AE
Glia; 2015 Mar; 63(3):400-11. PubMed ID: 25327891
[TBL] [Abstract][Full Text] [Related]
40. Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice.
Pennacchio LA; Bouley DM; Higgins KM; Scott MP; Noebels JL; Myers RM
Nat Genet; 1998 Nov; 20(3):251-8. PubMed ID: 9806543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
